Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Pacific Bio to Acquire Omniome for $800 Million in Sequencing Tie-up

publication date: Aug 3, 2021

Pacific Biosciences, a San Francisco Bay area company offering long-read sequencing platforms, will acquire Omniome, a San Diego short-read company, for up to $800 million. With the acquisition, PacBio will be the only company to offer highly accurate long-read and short-read sequencing programs. PacBio said combining the two technologies will expand its market and provide more value to clients. Decheng Capital, a Shanghai venture firm, led Omniome's $60 million Series B and participated in its $60 million Series C financing. More details....

Stock Symbol: (NSDQ: PACB)

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here


BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here


Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here